“Nocebo effect” accounts for 76% of all adverse events in the COVID-19 vaccine trial group

The placebo effect is a phenomenon known to improve a person’s physical or mental health after taking a treatment with no pharmacological benefit – a sugar pill, or a syringe filled with saline, for example. While the biological, psychological, and genetic underpinnings of the placebo effect are not well understood, some theories point to expectations … Read more

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Preliminary results from Penn Medicine in an ongoing first-ever human clinical trial examining the safety, tolerability, and feasibility of macrophage chimeric antigen (CAR-M) have helped demonstrate the feasibility of this innovative immunotherapy, which advances the scientific groundbreaking discovery of CAR T-cell therapy. In Penn- for Solid Cancer Tumors and presents a promising new strategy in … Read more

New combination immune therapy for cancer is effective and has fewer side effects, study finds

Google “chemotherapy side effects” and the results abound. Nausea, anemia, infection, fertility problems, kidney problems, mouth sores. And the list goes on and on. The inevitable downside of cancer treatment always seems to be a decrease in their quality of life. But a new study at Northwestern Medicine found that the new combination immunotherapy not … Read more

SGLT2 inhibitor empagliflozin can be used to treat insulin resistance in the brain, finds study

Overweight or obesity, unwanted distribution of body fat and the development of type 2 diabetes are often associated with a decreased effect of the hormone insulin in many organs, including the brain (insulin resistance). So far there is no treatment to restore insulin sensitivity in the brain, which plays a key role in controlling metabolism. … Read more

Single-patient pilot study shows the ability of antisense oligonucleotide to suppress mutant ALS gene

Using a synthetic short chain of chemically modified nucleotides engineered at the Institute of RNA Therapeutics at UMass Chan School of Medicine, Robert H. The ALS gene known as C9ORF72 in a pilot study of a single patient. C9ORF72 is the most common cause of familial amyotrophic lateral sclerosis (ALS) and familial frontotemporal dementia (FTD). … Read more

Wistar announces initiation of Phase 2 clinical study of VK-2019 in patients with advanced head and neck cancer

The Wistar Institute announces the start of a phase II clinical study of VK-2019 in patients with advanced Epstein-Barr Carcinoma (EBV)-nasopharyngeal carcinoma (NPC) and lymphoma. The study, which is being led by researchers at Stanford University School of Medicine, will include patients who have recurred, progressed after standard treatment, or who have not responded to … Read more

New drug targeting LF and onchocerciasis begins its first in human trial in Liverpool

A new drug developed by a partnership led by LSTM, which targets neglected tropical diseases, lymphatic filariasis and onchocerciasis, has begun its first human trial. Lymphatic filariasis and onchocerciasis are debilitating diseases that affect more than 150 million people worldwide. Both are caused by parasitic worms, and this specific drug AWZ1066S was designed to targetWolbachia, … Read more